Longeveron (LGVN) Net Cash Flow (2020 - 2026)
Longeveron (LGVN) posted quarterly Net Cash Flow of $11.1 million for Q1 2026, up 326.24% year-over-year from $2.6 million in Q1 2025, and up 342.13% quarter-over-quarter from -$4.6 million in Q4 2025.
Longeveron (LGVN) Net Cash Flow (2020 - 2026) Analysis & Trends
Longeveron's Net Cash Flow history runs 7 years deep, the most recent figure standing at $11.1 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 326.24% year-over-year to $11.1 million; the TTM figure through Mar 2026 stood at $1.4 million (down 88.45% YoY), while the FY2025 annual figure was -$14.6 million, down 202.02% from the prior year.
- Net Cash Flow for Q1 2026 stood at $11.1 million, up from -$4.6 million in the prior quarter.
- The five-year high for Net Cash Flow was $11.1 million in Q1 2026, with the low at -$6.6 million in Q3 2022.
- The 5-year median for Net Cash Flow is -$3.0 million (2024), against an average of -$582352.9.
- Peak annual rise in Net Cash Flow reached 1433.72% in 2024, while the deepest fall reached 218.91% in 2024.
- Longeveron's Net Cash Flow stood at -$3.1 million in 2022, then soared by 197.1% to $3.0 million in 2023, then sank by 218.91% to -$3.5 million in 2024, then slipped by 29.24% to -$4.6 million in 2025, then surged by 342.13% to $11.1 million in 2026.
- Business Quant data shows LGVN's Net Cash Flow at $11.1 million in Q1 2026, -$4.6 million in Q4 2025, and -$1.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -5.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.68 Mn |
| Jun 30, 2026 | -5.68 Mn |
| Mar 31, 2026 | 11.10 Mn |
| Mar 31, 2026 | 11.10 Mn |
| Dec 31, 2025 | -4.58 Mn |
| Dec 31, 2025 | -4.58 Mn |
| Sep 30, 2025 | -1.09 Mn |
| Sep 30, 2025 | -1.09 Mn |
| Jun 30, 2025 | -3.99 Mn |
| Jun 30, 2025 | -3.99 Mn |
| Mar 31, 2025 | -4.91 Mn |
| Mar 31, 2025 | -4.91 Mn |
| Dec 31, 2024 | -3.55 Mn |
| Dec 31, 2024 | -3.55 Mn |
| Sep 30, 2024 | 10.40 Mn |
| Sep 30, 2024 | 10.40 Mn |
| Jun 30, 2024 | 10.44 Mn |
| Jun 30, 2024 | 10.44 Mn |
| Mar 31, 2024 | -3.01 Mn |
| Mar 31, 2024 | -3.01 Mn |